| Bioactivity | LAVYQAGA-Arg(13C6, 15N4) TFA is a peptide containing 13C6 and 15N4 labeled Arg[1]. |
| Invitro | 氢、碳和其他元素的稳定重同位素已被纳入药物分子中，主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注，因为它可能影响药物的药代动力学和代谢谱[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> LAVYQAGA-Arg(13C6,15N4) TFA 相关抗体: |
| Sequence | Leu-Ala-Val-Tyr-Gln-Ala-Gly-Ala-Arg(13C6,15N4) |
| Shortening | LAVYQAGA-Arg(13C6,15N4) |
| Formula | C3613C6H69N915N4O12.xC2HF3O2 |
| Molar Mass | 958.01 (free base) |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. |